Conbercept Biosimilar Fusion Protein (VEGF-A) for Research

Cat No.: GMP-Bios-INN-787

Pre-Made Conbercept Biosimilar, Fusion Protein targeting VEGFA fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting MVCD1/VEGF/VPF is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Conbercept, sold under the commercial name Lumitin, is a novel vascular endothelial growth factor (VEGF) inhibitor used to treat neovascular age-related macular degeneration (AMD)[1][2] and diabetic macular edema (DME).[3] The anti-VEGF was approved for the treatment of neovascular AMD by the China State FDA (CFDA) in December 213.[4][5] As of December 22, conbercept is undergoing phase III clinical trials through the U.S. Food and Drug Administration’s PANDA-1 and PANDA-2 development programs.[6][7]

Conbercept, is a novel vascular endothelial growth factor (VEGF) inhibitor used to treat neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). Conbercept is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to the Fc portion of human IgG1 immunoglobulin. Conbercept is a soluble receptor decoy that binds specifically to VEGF-B, placental growth factor (PlGF), and various isoforms of VEGF-A. Conbercept has a VEGF-R2 kinase insert domain receptor (KDR) Ig-like region 4 (KDRd4) which improves the three-dimensional structure and efficiency of dimer formation, thereby increasing the binding capacity of conbercept to VEGF.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-787-1mg 1mg 3090
GMP-Bios-INN-787-10mg 10mg
GMP-Bios-INN-787-100mg 100mg
GMP-Bios-INN-787-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Conbercept Biosimilar, Fusion Protein targeting VEGFA fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting MVCD1/VEGF/VPF
INN Name Conbercept
TargetVEGFA
FormatFusion Protein
Derivationhuman
Species Reactivityhuman
CH1 IsotypeFusion - [FLT1 (fms- related tyrosine kinase 1, vascular endothelial growth factor receptor 1, VEGFR-1, VEGFR, FLT, FRT, vascular permeability factor receptor) - KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, VEGF- R2, FLK1, CD309)]2 - IGHG1 Fc (Fragment constant)
VD LCFusion - [FLT1 (fms- related tyrosine kinase 1, vascular endothelial growth factor receptor 1, VEGFR-1, VEGFR, FLT, FRT, vascular permeability factor receptor) - KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, VEGF- R2, FLK1, CD309)]2 - IGHG1 Fc (Fragment constant)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesChengdu Kanghong Biotech Co.,Ltd. (China)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0



About target - VEGFA

1. Protein Vascular endothelial growth factor A

2. Gene VEGFA

3. Organism Homo sapiens (Human)

Function
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development (By similarity).